Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803407 | 0.99 | KCNH2 (0.33) | KCNH2HRH3CHRM2CHRM3POLB | |
| SCHEMBL5803044 | 0.91 | KMT2A (0.35) | POLBUSP2MEN1KMT2A | |
| SCHEMBL5912951 | 0.89 | POLB (0.30) | POLB | |
| SCHEMBL5799203 | 0.88 | — | — | |
| SCHEMBL5802233 | 0.84 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3563083 | 0.83 | CHRM2 (0.34) | CHRM2CHRM3POLBUSP2MEN1 | |
| SCHEMBL3566118 | 0.81 | MAPT (0.32) | — | |
| SCHEMBL3560663 | 0.80 | IDH1 (0.33) | — | |
| SCHEMBL3567221 | 0.76 | NPSR1 (0.30) | — | |
| SCHEMBL5803379 | 0.76 | TSHR (0.38) | POLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | TFPI, TFPI2, F12 | KCNH2 2062/4885HRH3 1959/4885CHRM2 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.